JW (Cayman) Therapeutics Co. Ltd.

As of December 31, 2025, JW (Cayman) Therapeutics Co. Ltd. carries a market capitalization of 1.05B, placing it among publicly traded companies globally. Its enterprise value stands at 777.69M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

JW (Cayman) Therapeutics Co. Ltd.'s next confirmed earnings release is scheduled for April 1, 2027.

As of December 31, 2025, JW (Cayman) Therapeutics Co. Ltd. has 416.47M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, JW (Cayman) Therapeutics Co. Ltd. maintains a current ratio of 1.45, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, JW (Cayman) Therapeutics Co. Ltd.'s stock has declined approximately 33.03% over the past 52 weeks. The 50-day moving average sits at 2.33, while the 200-day moving average is 2.16.

As of December 31, 2025, JW (Cayman) Therapeutics Co. Ltd. holds 559.86M in cash and equivalents against 292.20M in total debt, resulting in a net debt position of -297.11M. Total book value stands at 619.06M, with working capital of 195.77M providing operational flexibility.